Skip to main content
. 2018 Feb 2;9(2):146. doi: 10.1038/s41419-017-0177-2

Fig. 6. RAP80 deficiency remarkably sensitizes EC cells to cisplatin treatment.

Fig. 6

a, b EC109 (a) and EC1 (b) cells infected with shCon. or shRAP80 #1 were treated with or without cisplatin and then subjected to immunofluorescence (IF) assays to test the formation of γH2AX foci. The percentage of γH2AX foci-positive cells at different levels (−,+, ++) was statistically analyzed. Representative results were shown. Scale bar, 5 μm. c EC1/shCon. and EC1/shRAP80 #1 cells treated with or without cisplatin were subjected to the neutral comet assays. The olive tail moment was used to assess the damage severity. d EC109/shCon. and EC109/shRAP80 #1 cells treated with or without cisplatin were subjected to IF assays to test the BRCA1 (Green) and RAD51 (Red) foci formation. Representative results were shown. Scale bar, 5 μm